SCHEMBL19975239

SCHEMBL19975239

O=C(O)C1CCC(=O)N1CCC1CCOCC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.40
ACE P12821 2/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 2/20 0.36
FEN1 P39748 1/20 0.34
CNR2 P34972 3/20 0.34
CNR1 P21554 2/20 0.34
KCNH2 Q12809 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
PTGER4 P35408 1/20 0.32
PTGER3 P43115 1/20 0.32
PTGER2 P43116 1/20 0.32
S1PR5 Q9H228 1/20 0.32
TSHR P16473 1/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975022 0.89 SMN1; SMN2 (0.39) SMN1; SMN2CYP2C19ALDH1A1FEN1CNR2
SCHEMBL19975108 0.85 FEN1 (0.41) SMN1; SMN2ACECYP2C19ALDH1A1FEN1
SCHEMBL19975082 0.83 ALDH1A1 (0.40) SMN1; SMN2CYP2C19ALDH1A1CNR2CNR1
SCHEMBL19975249 0.77 CYP2C19 (0.37) SMN1; SMN2CYP2C19ALDH1A1MEN1POLB
SCHEMBL8761596 0.74 P2RX7 (0.46) ACEALDH1A1MEN1POLBKMT2A
SCHEMBL19974787 0.73 FEN1 (0.37) SMN1; SMN2ACECYP2C19ALDH1A1FEN1
Hydrochloric Acid SCHEMBL8895919 0.73 ACE (0.41) SMN1; SMN2ACECYP2C19ALDH1A1MEN1
SCHEMBL19975095 0.73 ACE (0.43) ACEALDH1A1MEN1POLBKMT2A
SCHEMBL8762017 0.72 MEN1 (0.57) ACEALDH1A1MEN1POLBKMT2A
SCHEMBL29833530 0.72 MEN1 (0.57) ACEALDH1A1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C SMN1; SMN2 706/4885ACE 94/4885CYP2C19 3198/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C SMN1; SMN2 1086/4885ACE 145/4885CYP2C19 3143/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C SMN1; SMN2 706/4885ACE 94/4885CYP2C19 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.